Compare Novo Nordisk A/S (NVO) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs STMicroelectronics NV — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while STMicroelectronics NV trades at $52.14 (market cap $48.14B). The key difference: Novo Nordisk A/S is far larger — about 3.4× STMicroelectronics NV's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and STMicroelectronics NV for 64 Days on average.
| NVO | STM | |
|---|---|---|
Market Cap | $165.31B | $48.14B |
Volume | 11,432,838 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $63.98 | $79.91 |
52-Week Low | $35.29 | $21.20 |
Typical Hold Time | 116 Days | 64 Days |
Enterprise Value | $179.56B | $45.66B |
Dividend Yield | 4.71% | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
STM is trading at $52.06, down 7.33% over 24 hours amid broader tech sector pressure. The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment, including a $77.31 consensus price target. Recent earnings have been volatile with two misses and one beat in the last three quarters, while the company maintains strong cash flow generation of $555 million in 2025. STM is positioning for AI data-center revenue growth, targeting over $2 billion by 2027, with recent product launches in automotive imaging and edge AI partnerships.
The outlook remains cautiously optimistic given STM's strategic positioning in AI infrastructure and automotive semiconductors, though near-term margin pressures from facility transitions and competitive dynamics pose risks. The 48% upside to consensus target suggests Wall Street sees recovery potential, but investors should monitor execution on AI revenue targets and margin improvement through 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
